Magnecine — Full Investor Presentation

How the Compound Works

A Dual‑Action Synergistic Therapy Designed for Disc‑Related Pain

The patented compound combines colchicine and magnesium chloride in an intravenous formulation engineered to target the biological drivers of pain caused by herniated or damaged intervertebral discs. Each ingredient contributes powerful, scientifically established mechanisms — but the true innovation lies in how they work together, producing effects neither achieves alone.

1. Colchicine: Inflammation Control at the Cellular Level

Colchicine binds to β‑tubulin, disrupting microtubules inside inflammatory cells. This blocks several key processes involved in disc‑related pain: neutrophil activation and migration; NLRP3 inflammasome assembly (a major source of IL‑1β and IL‑18); cytokine release (TNF‑α, IL‑1β, IL‑6); axonal transport of pain mediators such as substance P and CGRP. These actions reduce inflammation, neurogenic irritation, and peripheral sensitization around the affected disc and nerve root.

2. Magnesium Chloride: Neuro‑Modulation, Vasodilation, and Antioxidant Support

Magnesium chloride contributes three major therapeutic actions: NMDA receptor modulation, reducing central sensitization in the spinal cord; vasodilation, improving microvascular blood flow to compressed nerve roots; reduction of oxidative stress and NF‑κB–driven inflammation. These mechanisms address both the neuropathic and inflammatory components of discogenic pain.

3. Breakthrough Synergy: Magnesium Extends Colchicine's Active Binding by 4–10 Hours

A key scientific finding supporting this patent is that magnesium delays the off‑loading of colchicine from its binding site on tubulin by 4–10 hours. This means: colchicine stays bound longer; microtubule disruption lasts longer; inflammatory cell activity remains suppressed longer; pain‑mediating neuropeptides remain reduced longer. This is a true pharmacokinetic–pharmacodynamic enhancement: magnesium does not merely add its own effects — it amplifies and prolongs colchicine's core mechanism.

4. Enhanced Delivery: Magnesium‑Driven Vasodilation Increases Colchicine Penetration

When administered together, magnesium's vasodilating effect increases local blood flow, allowing more colchicine to reach the target tissues, including inflamed nerve roots, perineural tissues, and disc‑adjacent microvasculature. This improves colchicine's bioavailability at the exact anatomical sites where inflammation and pain originate. In other words, magnesium does not just enhance colchicine's duration — it enhances its delivery.

5. Multi‑Layered Mechanism Targeting All Major Drivers of Disc Pain

Together, the two ingredients create a comprehensive therapeutic profile: inflammation suppression (dual‑pathway: microtubules + NF‑κB); reduced oxidative stress; improved microvascular perfusion; reduced peripheral and central sensitization; extended duration of action through magnesium‑induced binding stabilization; improved colchicine delivery through vasodilation. This combination addresses the full biological complexity of disc‑related pain in a way that single‑agent therapies cannot.

6. Why This Matters for Commercial Value

The compound's innovation is based on three patent‑defining advantages: a novel synergistic mechanism — magnesium prolongs colchicine's binding and enhances its delivery; a multi‑pathway biological effect — inflammation, oxidative stress, neurovascular dysfunction, and sensitization are all targeted simultaneously; a unique IV formulation designed for rapid systemic distribution and optimized tissue penetration. This positions the compound as a first‑in‑class mechanistically synergistic therapy for conditions involving disc‑related inflammation and nerve root irritation.